Frontiers in Genetics,
Journal Year:
2023,
Volume and Issue:
14
Published: Dec. 15, 2023
Ulcerative
colitis
(UC)
is
an
inflammatory
bowel
disease,
and
characterized
by
the
diffuse
inflammation
ulceration
in
colon
rectum
mucosa,
even
extending
to
caecum.
Epigenetic
modifications,
including
DNA
methylations,
histone
modifications
non-coding
RNAs,
are
implicated
differentiation,
maturation,
functional
modulation
of
multiple
immune
non-immune
cell
types,
influenced
altered
various
chronic
diseases,
UC.
Here
we
review
relevant
studies
revealing
differential
epigenetic
features
UC,
summarize
current
knowledge
about
immunopathogenesis
UC
through
regulation
signaling
networks,
regarding
methylation,
modification,
miRNAs
lncRNAs.
We
also
discuss
epigenetic-associated
therapeutic
strategies
for
alleviation
treatment
which
will
provide
insights
intervene
immunopathological
process
view
regulation.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Feb. 12, 2024
When
an
organism
encounters
a
pathogen,
the
host
innate
immune
system
activates
to
defend
against
pathogen
colonization
and
toxic
xenobiotics
produced.
PubMed,
Journal Year:
2024,
Volume and Issue:
27(6), P. 761 - 767
Published: Jan. 1, 2024
Ulcerative
colitis
is
a
chronic
inflammatory
bowel
disease
(IBD)
that
causes
inflammation
and
ulcers
in
the
rectum
innermost
layer
of
large
intestine.
Our
study
aimed
to
elucidate
ameliorative
effect
cetirizine
(CTZ)
loratadine
(LOR)
against
acetic
acid-induced
ulcerative
rats
via
assessment
PI3K/p-Akt/Nrf2
signaling
pathway
proinflammatory
cytokine
release.
Saudi Pharmaceutical Journal,
Journal Year:
2023,
Volume and Issue:
32(1), P. 101910 - 101910
Published: Dec. 10, 2023
Ulcerative
colitis
(UC)
is
an
inflammatory
condition
of
colon
characterized
by
severe
damage
to
the
innermost
tissues.
A
number
studies
described
use
medication
delivery
systems
based
on
natural
polymers
like
polysaccharides
for
purpose
reaching
colon.
In
this
research,
polymer-based
mesalamine
delayed-release
granules
(DRGs)
were
tested
their
antioxidant
and
anti-inflammatory
efficacy
against
UC.
Chitosan
(C),
pectin
(P),
pectin-chitosan
(PC)
(M)
DRGs
prepared
characterized.
Data
revealed
satisfactory
compatibility,
flow,
packing
properties,
drug
release
pattern,
delayed
DRGs.
Wistar
rats
treated
with
2,4,6-trinitrobenzenesulfonic
acid
(TNBS)
(100
mg/kg)
via
rectal
administration.
Mesalamine
(50
administered
orally
separately
14
days.
Biomarkers
oxidative
stress,
inflammation,
hematological
tests,
profile,
histopathology
performed.
The
findings
demonstrated
good
in
delivering
various
showed
significant
effects
significantly
attenuated
lipid
peroxidation,
nitrites,
myeloperoxidase
activity,
interleukin-1β
levels,
improved
anti-oxidants
(GSH,
SOD).
upregulation
Nrf2
activity
CM-DRGs
showing
maximum
effect.
different
TNBS-induced
decline
body
weight,
ulcer
severity,
damage.
most
pronounced
ameliorative
effect
hematology
parameters
anti-oxidant
activities.
can
be
used
as
a
carrier
oral
DRG
formulation
enhanced
therapeutic
Frontiers in Genetics,
Journal Year:
2023,
Volume and Issue:
14
Published: Dec. 15, 2023
Ulcerative
colitis
(UC)
is
an
inflammatory
bowel
disease,
and
characterized
by
the
diffuse
inflammation
ulceration
in
colon
rectum
mucosa,
even
extending
to
caecum.
Epigenetic
modifications,
including
DNA
methylations,
histone
modifications
non-coding
RNAs,
are
implicated
differentiation,
maturation,
functional
modulation
of
multiple
immune
non-immune
cell
types,
influenced
altered
various
chronic
diseases,
UC.
Here
we
review
relevant
studies
revealing
differential
epigenetic
features
UC,
summarize
current
knowledge
about
immunopathogenesis
UC
through
regulation
signaling
networks,
regarding
methylation,
modification,
miRNAs
lncRNAs.
We
also
discuss
epigenetic-associated
therapeutic
strategies
for
alleviation
treatment
which
will
provide
insights
intervene
immunopathological
process
view
regulation.
